CAS: 8052-16-2; Actinochrysin C

该化合物是Actinologycin集团的一个聚苯二苯并呋喃抗生素,以其强大的抗扰和抗微生物特性而闻名,它通过切入DNA,抑制RNA合成和干扰转录过程发挥作用.这个复合物对于某些模范阳性细菌及其在涉及核糖酸相互作用的研究应用中作用的效果特别显著.Actimomiccin C与双层DNA具有高度的粘合性,使它成为分子生物学研究的宝贵工具.它在受控条件下的稳定性和精确的行动机制进一步提高了它在治疗和实验环境中的效用.由于细胞毒性的性质,适当的处理是必不可少的.

结构式图片

欧盟法规

C&L通报REACH预注册

合成工艺路线路线简述

    📜Methyl (5Z,8E)-8-Formyl-10,10-Dimethoxy-5,8-Decadienoate 在 Chromium(Vi) Oxide,六甲基磷酰三胺,正丁基锂,四甲基乙二胺,Celite体系中,用 四氢呋喃,吡啶,正己烷,二氯甲烷作为反应溶剂,反应 1.25H,获得 2-Amino-1-N-[(3R,6S,7R,10S,16S)-3-[(2S)-Butan-2-Yl]-7,11,14-Trimethyl-2,5,9,12,15-Pentaoxo-10-Propan-2-Yl-8-Oxa-1,4,11,14-Tetrazabicyclo[14.3.0]Nonadecan-6-Yl]-4,6-Dimethyl-3-Oxo-9-N-[(3R,6S,7R,10S,16S)-7,11,14-Trimethyl-2,5,9,12,15-Pentaoxo-3,10-Di(Propan-2-yl)-8-Oxa-1,4,11,14-Tetrazabicyclo[14.3.0]Nonadecan-6-Yl]Phenoxazine-1,9-Dicarboxamide
    参考文献:血栓烷a 2类似物的合成-4:(+/-)-二硫代血栓烷a 2钠盐
    标题:血栓烷a 2类似物的合成-4:(+/-)-二硫代血栓烷a 2钠盐
    摘要:(+/-)-二硫代血栓烷a 2钠盐1的总合成是由4,4-二甲氧基乙酰乙酸甲酯分26个步骤完成的.
    Doi:10.1016/S0040-4020(01)88651-8

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-12391691-B2
    优先权日:2018-11-16
    标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
    发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
    权利人:AMGEN INC
    摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

    专利号:US-2025206736-A1
    优先权日:2019-11-14
    标题 :Synthesis of kras g12c inhibitor compound
    发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
    权利人:AMGEN INC
    摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

    专利号:US-2017283878-A1
    优先权日:2015-12-11
    标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
    发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
    权利人:ACADEMIA SINICA
    摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

    专利号:US-2022233673-A1
    优先权日:2019-06-04
    标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
    发明人:BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M
    权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND
    摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.

    专利号:WO-2023008461-A1
    优先权日:2021-07-27
    标题:Medicament for treatment and/or prevention of cancer
    发明人:KUME MASAHIKO; OKANO FUMIYOSHI; SAITO TAKANORI
    权利人:TORAY INDUSTRIES
    摘要:The present invention relates to a medicament for the treatment and/or prevention of cancer, the medicament being characterized by comprising an antibody having an immunological reactivity with CAPRIN-1 protein or a fragment of the antibody and a drug capable of inhibiting the N-glycoside-linked sugar chain synthesis of a glycoprotein which are combined with each other in a blended or separated form.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Shah AM, Shakeel-U-Rehman, Hussain A, Mushtaq S, Rather MA, Shah A, Ahmad Z, Khan IA, Bhat KA, Hassan QP. Antimicrobial investigation of selected soil actinomycetes isolated from unexplored regions of Kashmir Himalayas, India. Microb Pathog. 2017 Sep;110:93-99. doi: 10.1016/j.micpath.2017.06.017. Epub 2017 Jun 22. 351(6270):275-281. doi: 10.1126/science.aab4138.
    3: Steinman J, Ariyan C, Rafferty B, Brady MS. Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. J Surg Oncol. 2014 Apr;109(5):405-9. doi: 10.1002/jso.23519. Epub 2013 Dec 7. 79(2):257-60. doi: 10.1016/j.bioelechem.2010.02.005. Epub 2010 Mar 10. 12(4):851-66. doi: 10.1677/erc.1.01039. 88(1):39-51. doi: 10.1093/toxsci/kfi282. Epub 2005 Aug 10. 434(2):306-15. doi: 10.1016/j.abb.2004.11.016. 54(4):519-25. Russian. 49(8):602-16. 28(7):497-502. doi: 10.1016/j.cellbi.2004.04.003. 58(4):1208-14. doi: 10.1016/j.ijrobp.2003.08.027. 270(8):1735-45. doi: 10.1046/j.1432-1033.2003.03532.x. 24(2):148-50. doi: 10.1002/bem.10082. (3):35-40. Russian. 290(3):1019-25. 244(3):861-7. doi: 10.1006/bbrc.1998.8363. Erratum in: Biochem Biophys Res Commun 1998 Jul 20;248(2):441. 236(3):636-40. doi: 10.1006/bbrc.1997.7021. 61(3):367-74. doi: 10.1002/jlb.61.3.367. 107(6):856-9. doi: 10.1111/1523-1747.ep12331160. 39(2-3):22-5. Russian.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知